RNTX
Rein Therapeutics, Inc.Company Information
- Company Name
- Rein Therapeutics, Inc.
- CIK
- CIK0001420565
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- RNTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RNTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-27
- Last sale
- 2024-06-17
- Shares purchased (TTM)
- 312,075
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 40,826,266
- Shares outstanding
- 67,084,661
- Ownership
- 60.86%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 10.30%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 9 | 4 | 3 | 4 | 6 | 7 | 13 | 18 | 22 | 12 | 17 | 12 | ||||||
| Short Term Investments | 32 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 41 | 5 | 4 | 5 | 7 | 8 | 14 | 19 | 23 | 13 | 18 | 13 | ||||||
| Property Plant And Equipment Net | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Goodwill | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | - | ||||||
| Intangible Assets Net Excluding Goodwill | 14 | 14 | 14 | 42 | 42 | 42 | 42 | 79 | 79 | 79 | 79 | - | ||||||
| Long Term Investments | 3 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 2 | - | ||||||
| Assets | 66 | 26 | 24 | 54 | 57 | 58 | 62 | 104 | 109 | 99 | 106 | 13 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 6 | 4 | 4 | 6 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | ||||||
| Accrued Liabilities And Other Liabilities | 2 | 2 | 2 | 2 | 2 | 5 | 5 | 5 | 4 | 2 | 3 | 1 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Notes Payable Current | - | 5 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 10 | 14 | 6 | 6 | 8 | 6 | 6 | 6 | 5 | 5 | 4 | 2 | ||||||
| Deferred Income Tax Liabilities Net | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | - | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | ||||||
| Liabilities | 11 | 15 | 7 | 8 | 9 | 8 | 8 | 9 | 8 | 8 | 8 | 2 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 47 | 91 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Shares Subscriptions | - | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 424 | 374 | 373 | 370 | 367 | 362 | 361 | 361 | 361 | 340 | 295 | 292 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - | ||||||
| Retained Earnings Accumulated Deficit | -413 | -407 | -401 | -369 | -364 | -357 | -351 | -310 | -305 | -296 | -289 | -281 | ||||||
| Liabilities And Stockholders Equity | 66 | 26 | 24 | 54 | 57 | 58 | 62 | 104 | 109 | 99 | 106 | 13 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 5 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Temporary Equity Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Stockholders Equity | - | - | - | - | - | - | - | - | - | - | 7 | 11 | ||||||
| Temporary Equity Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | ||||||
| Temporary Equity Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Temporary Equity Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 45 | 45 | ||||||
| Common Stock Shares Issued | 86 | 28 | 28 | 25 | 23 | 22 | 22 | 22 | 22 | 17 | 5 | 5 | ||||||
| Shares Outstanding | 86 | 28 | 28 | 25 | 23 | 22 | 22 | 22 | 22 | 17 | 5 | 5 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRein Therapeutics, Inc. (RNTX) — SEC Financial Statements & Analysis
Rein Therapeutics, Inc. (RNTX) is a pharmaceutical preparations company. Rein Therapeutics, Inc. trades on Nasdaq as: RNTX. Rein Therapeutics, Inc. (RNTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Rein Therapeutics, Inc. carries a market cap of $69.77M, a P/E ratio of -1.40x, a P/B ratio of 1.26x, an enterprise value of $61.23M, and an EV/EBITDA multiple of -1.24x. On profitability, it posts a Return on Equity (ROE) of -96.42%, a Return on Assets (ROA) of -80.62%, and a Return on Invested Capital (ROIC) of -111.20%. Per share, it reports EPS of $-0.74, diluted EPS of $-0.74, free cash flow per share of $-0.28, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -15.87% year-over-year and EPS growth of -69.67% year-over-year. On the balance sheet, it maintains a current ratio of 4.27x, a quick ratio of 4.19x, working capital of $31.74M, a debt-to-equity ratio of 0.20x, a debt ratio of 0.16, an interest coverage ratio of -164.63x, free cash flow of $-18.83M (TTM), and net debt of $-8.54M. Figures sourced from SEC EDGAR.
- Market Cap
- $69.77M
- P/E TTM
- -1.40x
- EPS TTM
- $-0.74
- P/B TTM
- 1.26x
- ROE TTM
- -96.42%
- ROA TTM
- -80.62%
- Debt To Equity
- 0.20x
- Free Cash Flow TTM
- $-18.83M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Rein Therapeutics, Inc. in?
Rein Therapeutics, Inc. (RNTX) operates in the Pharmaceutical Preparations industry.
What exchange does RNTX trade on?
Rein Therapeutics, Inc. (RNTX) trades on the Nasdaq.
When was Rein Therapeutics, Inc. (RNTX)'s most recent SEC filing?
Rein Therapeutics, Inc. (RNTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is RNTX's market cap?
Rein Therapeutics, Inc. (RNTX) has a market capitalization of $69.77M as of 2026-06-30.
What is RNTX's EPS (earnings per share)?
Rein Therapeutics, Inc. (RNTX)'s trailing twelve month EPS is $-0.74 as of 2026-06-30.
What is RNTX's ROE (return on equity)?
Rein Therapeutics, Inc. (RNTX)'s trailing twelve month Return on Equity (ROE) is -96.42% as of 2026-06-30.
What is RNTX's ROA (return on assets)?
Rein Therapeutics, Inc. (RNTX)'s trailing twelve month Return on Assets (ROA) is -80.62% as of 2026-06-30.
What is RNTX's ROIC (return on invested capital)?
Rein Therapeutics, Inc. (RNTX)'s trailing twelve month Return on Invested Capital (ROIC) is -111.20% as of 2026-06-30.
What is RNTX's EV/EBITDA?
Rein Therapeutics, Inc. (RNTX)'s trailing twelve month EV/EBITDA is -1.24x as of 2026-06-30.